Circulating miR-618 Has Prognostic Significance in Patients with Metastatic Colon Cancer.
metastatic colon cancer
miR-618
rs2682818
Journal
Current oncology (Toronto, Ont.)
ISSN: 1718-7729
Titre abrégé: Curr Oncol
Pays: Switzerland
ID NLM: 9502503
Informations de publication
Date de publication:
15 03 2021
15 03 2021
Historique:
received:
27
01
2021
revised:
28
02
2021
accepted:
11
03
2021
entrez:
3
4
2021
pubmed:
4
4
2021
medline:
25
9
2021
Statut:
epublish
Résumé
The present study evaluated the prognostic role of circulating miRNA-618 in patients with metastatic colon cancer (mCC) and whether miR-618 gene rs2682818 single nucleotide polymorphisms (SNP) are associated with colon cancer susceptibility and expression levels of mature miR-618. In total, 104 patients with mCC before starting the chemotherapy were investigated. The expression status of circulating miR-618 in mCC was evaluated by quantitative PCR. TaqMan PCR assay was used for rs2682818 SNP genotyping. miR-618 was overexpressed in serum of mCC patients. Patients with high and intermediate expression of miR-618 had a significantly longer mean overall survival (OS) of 21 months than patients with low expression-16 months. In addition, multivariate Cox regression analysis confirmed the association between high/intermediate levels of miRNA-618 and longer OS, HR = 0.51, 95% CI: 0.30-0.86,
Identifiants
pubmed: 33804070
pii: curroncol28020116
doi: 10.3390/curroncol28020116
pmc: PMC8025826
doi:
Substances chimiques
MIRN618 microRNA, human
0
MicroRNAs
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1204-1215Références
J BUON. 2020 Jul-Aug;25(4):1805-1813
pubmed: 33099917
Cancer Prev Res (Phila). 2013 Mar;6(3):196-205
pubmed: 23466817
Indian J Cancer. 2015 Dec;52 Suppl 3:E186-9
pubmed: 27453421
Cancers (Basel). 2020 Oct 28;12(11):
pubmed: 33126409
Cell Biosci. 2019 Dec 2;9:97
pubmed: 31827763
Life Sci. 2020 May 1;248:117473
pubmed: 32114007
Chin J Cancer. 2011 Jun;30(6):381-91
pubmed: 21627860
J Clin Med. 2020 Aug 04;9(8):
pubmed: 32759718
Biosci Rep. 2019 Aug 23;39(8):
pubmed: 31383788
Cancer Med. 2018 Apr;7(4):1194-1200
pubmed: 29533012
Biochem Biophys Res Commun. 2020 Jun 4;526(3):713-720
pubmed: 32253030
Hum Mol Genet. 2007 Apr 15;16 Spec No 1:R14-20
pubmed: 17613544
Aging (Albany NY). 2019 Aug 6;11(15):5351-5367
pubmed: 31386627
BMC Cancer. 2018 Oct 19;18(1):992
pubmed: 30340564
CA Cancer J Clin. 2020 May;70(3):145-164
pubmed: 32133645
Cell Physiol Biochem. 2018;51(4):1710-1722
pubmed: 30504704
PLoS One. 2013;8(3):e58159
pubmed: 23483985
Transl Res. 2013 Oct;162(4):258-68
pubmed: 23933284
J Cancer. 2012;3:19-31
pubmed: 22211142
Ann Endocrinol (Paris). 2014 Sep;75(4):187-93
pubmed: 25145559
J Cancer. 2017 Aug 2;8(13):2501-2510
pubmed: 28900488
World J Gastroenterol. 2012 Jul 28;18(28):3745-51
pubmed: 22851869
Ann Oncol. 2014 Sep;25 Suppl 3:iii1-9
pubmed: 25190710
PLoS One. 2019 Aug 30;14(8):e0222013
pubmed: 31469874
Curr Opin Oncol. 2005 Jan;17(1):49-54
pubmed: 15608513
Anat Rec (Hoboken). 2019 Jun;302(6):931-940
pubmed: 30737902
Clin Epigenetics. 2018 Apr 23;10:59
pubmed: 29713393
Cancer Res. 2017 May 1;77(9):2339-2350
pubmed: 28249903
PLoS One. 2021 Jan 26;16(1):e0246083
pubmed: 33497386
Sci Rep. 2020 Mar 27;10(1):5644
pubmed: 32221351
Epigenetics. 2014 May;9(5):730-7
pubmed: 24503492
Transl Oncol. 2019 Mar;12(3):475-484
pubmed: 30594036
Onco Targets Ther. 2019 Nov 15;12:9795-9807
pubmed: 31814737
Oncol Rep. 2016 Jun;35(6):3321-30
pubmed: 27035560
Front Endocrinol (Lausanne). 2019 Jun 12;10:385
pubmed: 31249556
Front Oncol. 2018 Dec 13;8:596
pubmed: 30619739
PLoS One. 2012;7(10):e46684
pubmed: 23056401
Science. 1988 Jun 3;240(4857):1285-93
pubmed: 3287615
Oncol Rep. 2013 Oct;30(4):1949-56
pubmed: 23877086